Copyright © Inderes 2011 - present. All rights reserved.

Xintela

0.26 SEK

-2.26 %

Less than 1K followers

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.26 %
-40.27 %
-30.56 %
-40.82 %
-21.09 %
-17.07 %
-50.11 %
-86.40 %
-88.69 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Read more
Market cap
223.07M SEK
Turnover
20.83K SEK
Revenue
4.22M
EBIT %
-934.83 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.2
2026

Annual report '25

ShowingAll content types
Third party research

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Xintela: Awaiting final follow-up data - VH Corp

• The 24-month follow-up data to be reported by the end of Q3 • The GMP production facility is generating revenue • Adjusted for dilution, our fair value amounts to SEK 1.28 per share Xintela’s half-year report did not reveal any surprises. As announced...

Xintela
Third party research

Xintela: Taking position for the next phase - VH Corp

• Encouraging interim results with XSTEM OA • EQGen licensing deal signed regarding EQSTEM • Our fair value amounts to SEK 1.49 per share During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis...

Xintela
Third party research

Xintela: Licensing deal with EQGen Biomedical - VH Corp

• Q&A with EQGen’s founders CMO Willem Scheele and CEO Grant Senner • License fee of MUSD 1 and shares in EQGen worth MUSD 3 • Our model suggests a fair value of SEK 1.43 per share Xintela and EQGen have entered a licensing and development agreement ...

Xintela
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.